Song, Yanqin team published research in Nanoscale in 2021 | 4224-70-8

HPLC of Formula: 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Vinyl bromides undergo the Heck reaction, which involves C-C coupling with alkene to give substituted alkenes. 4224-70-8, formula is C6H11BrO2, Name is 6-Bromohexanoic acid. Methyl bromide is a precursor in the manufacture of several chemicals and is employed as a soil sterilant, mainly for seed production. HPLC of Formula: 4224-70-8.

Song, Yanqin;Ismail, Muhammad;Shan, Qi;Zhao, Jianing;Zhu, Yanping;Zhang, Leiming;Du, Yuan;Ling, Longbing research published 《 ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways》, the research content is summarized as follows. Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder that has seriously affected human health worldwide and its current management requires more successful therapeutic approaches. The combination of nanomedicines and pathophysiol. into one system may provide an alternative strategy for precise RA treatment. In this work, a practical ROS-mediated liposome, abbreviated as Dex@FA-ROS-Lips that comprised synthetic dimeric thioether lipids (di-S-PC) and a surface functionalized with folic acid (FA), was proposed for dexamethasone (Dex) delivery. Incorporation with thioether lipids and a FA segment significantly improved the triggered release and improved the triggered release of cytotoxic Dex as well as the active targeting of RA, altering its overall pharmacokinetics and safety profiles in vivo. As proof, the designed Dex@FA-ROS-Lips demonstrated effective internalization by LPS-activated Raw264.7 macrophages with FA receptor overexpression and released Dex at the inflammatory site due to the ROS-triggered disassembly. I.v. injection of this Dex@FA-ROS-Lips into adjuvant-induced arthritis (AIA) mice led to its incremental accumulation in inflamed joint tissues and significantly alleviated the cartilage destruction and joint swelling via suppression of proinflammatory cytokines (iRhom2, TNF-α and BAFF), as compared to the effect of com. free Dex. Importantly, the Dex@FA-ROS-Lips nanoformulation showed better hemocompatibility with less adverse effects on the body weight and immune organ index of AIA mice. The anti-inflammatory mechanism of Dex@FA-ROS-Lips was further studied and it was found that it is possibly associated with the down-regulation of iRhom2 and the activation of the TNF-α/BAFF signaling pathway. Therefore, the integration of nanomedicines and the RA microenvironment using multifunctional Dex@FA-ROS-Lips shall be a novel RA treatment modality with full clin. potential, and based on the enhanced therapeutic effect, the signaling pathway of iRhom2/TNF-α/BAFF reasonably explained the mechanism of Dex@FA-ROS-Lips in anti-RA, which suggested a mol. target for RA therapy and other inflammatory diseases.

HPLC of Formula: 4224-70-8, 6-bromohexanoic acid is an organobromine compound comprising hexanoic acid having a bromo substituent at the 6-position. It derives from a hexanoic acid.
6-Bromohexanoic acid is a useful research compound. Its molecular formula is C6H11BrO2 and its molecular weight is 195.05 g/mol. The purity is usually 95%.
6-Bromohexanoic acid is useful for the preparation of anti-CTLA4 compounds as antitumor agents.
6-Bromohexanoic acid is a fatty acid that has been shown to be an effective agent for the treatment of cancer. It is used in gene therapy to inhibit the growth of cancer cells by binding to and then activating transcription factors. 6-Bromohexanoic acid can also be used as a chemotherapeutic agent and has been shown to cause apoptosis in monoclonal antibody-treated cells. 6-Bromohexanoic acid has pharmacokinetic properties that are similar to those of other fatty acids. The reaction solution was found to have high chemical stability, which may be due to the presence of nitrogen atoms. This reaction solution was found to adsorb onto the surface of monoclonal antibodies and cell culture, altering their properties., 4224-70-8.

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary